Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5074943 | 0.79 | CA1 (0.48) | — | |
| SCHEMBL1585468 | 0.78 | HTR6 (0.40) | — | |
| SCHEMBL30968079 | 0.74 | NTRK1 (0.36) | NTRK1 | |
| SCHEMBL16091256 | 0.74 | NTRK1 (0.36) | NTRK1 | |
| SCHEMBL1093136 | 0.70 | — | — | |
| SCHEMBL11927548 | 0.70 | — | — | |
| SCHEMBL4421419 | 0.68 | FDPS (0.41) | — | |
| SCHEMBL24670230 | 0.67 | HTR6 (0.41) | — | |
| SCHEMBL18804763 | 0.66 | GPR119 (0.34) | NTRK1 | |
| SCHEMBL4008412 | 0.66 | CSNK2A2 (0.38) | NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416263-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2023-12-28 | — | — | US | disclosed |
| US-11834455-B2 | Carm1 inhibitors and uses thereof | Epizyme, Inc. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834455-B2 | Carm1 inhibitors and uses thereof | Epizyme, Inc. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834455-B2 | Carm1 inhibitors and uses thereof | Epizyme, Inc. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230279020-A9 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230279020-A9 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230279020-A9 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20210155631-A1 | CARM1 INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2021-05-27 | — | — | US | disclosed |
| US-10633389-B2 | CARM1 inhibitors and uses thereof | Epizyme, Inc. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20190135819-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2019-05-09 | — | — | US | disclosed |
| US-20170320883-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2017-11-09 | — | — | US | disclosed |
| US-9738651-B2 | CARM1 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738651-B2 | CARM1 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738651-B2 | CARM1 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-08-22 | — | — | US | disclosed |
| WO-2016044641-A2 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20160039834-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-02-11 | — | — | US | disclosed |
| US-20160039834-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-02-11 | — | — | US | disclosed |
| US-20160039834-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-02-11 | — | — | US | disclosed |
| EP-2970219-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014144169-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210155631-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, TIAM1, ADRM1 | NTRK1 3855/4885 |
| US-20230279020-A9 | CARM1 INHIBITORS AND USES THEREOF | CARM1, TIAM1, ADRM1 | NTRK1 3855/4885 |
| US-20170320883-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, TIAM1, ADRM1 | NTRK1 3870/4885 |
| US-11834455-B2 | Carm1 inhibitors and uses thereof | CARM1, TIAM1, ADRM1 | NTRK1 3870/4885 |
| US-10633389-B2 | CARM1 inhibitors and uses thereof | CARM1, TIAM1, ADRM1 | NTRK1 3855/4885 |
| US-20190135819-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, TIAM1, ADRM1 | NTRK1 3855/4885 |
| US-20230416263-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, TIAM1, ADRM1 | NTRK1 3855/4885 |
| US-20160039834-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, TIAM1, ADRM1 | NTRK1 4099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.